Physician

Oncology

Dr. Emil J. Freireich, MD

Emil J. Freireich, MD practices Oncology. He went to medical school at University of Illinois College of Medicine. He received awards:"Fellow (FASCO)" and "Elected Member". Emil Freireich is also a published doctor. He has 44 publication published. The most recent publication is: Fludarabine, cyclophosphamide and rituximab achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.

Publications

Fludarabine, cyclophosphamide and rituximab achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.
The proceedings of the initial meeting of the society of hematologic oncology 2013.
Granulocyte concentrates from a single high-yield apheresis can be split to support multiple patients.
A prospective, randomized, double-blind study, comparing unirradiated to irradiated white blood cell transfusions in acute leukemia patients.
Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malig...
The Society of Hematologic Oncology (SOHO): Moving Forward in the Battle Against Hematologic Malignancies.
The history of leukemia therapy-a personal journey.
Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS.
Retrospect of hematologic malignancies 2010.
Leukocyte Transfusion and the Development of the Continuous-Flow Blood Cell Separator.
LDOC1 mRNA is differentially expressed in chronic lymphocytic leukemia and predicts overall survival in untreated patients.
25 years of peripheral blood stem cell transplantation.
Origins of Platelet Transfusion Therapy.
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia.
MER1, a novel organic arsenic derivative, has potent PML-RARalpha-independent cytotoxic activity against leukemia cells.
Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma.
The role of investigational therapy in management of patients with advanced metastatic malignancy.
Leukemia research, 2008.
Rethinking the randomized clinical trial: the 21st century application of Freireich's laws. [An interview with Emil J Freireich by H&O].
Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years.
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System.
Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia.
The prognostic significance of serum beta2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patients.
Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia.
Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of ...
Influence of high-efficiency particulate air filtration on mortality and fungal infection: a rebuttal.
Randomization in Phase II Clinical Trials.
Eradication of minimal residual disease in hairy cell leukemia.
Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte tra...
Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation.
Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986.
Metastasis--an alternative hypothesis.
Impact of high-dose granulocyte transfusions in patients with cancer with candidemia: retrospective case-control analysis of 491 episodes of Candida species bloodstrea...
Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute l...
Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting.
Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia.
Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha.
Bone marrow purging studies in acute myelogenous leukemia using the recombinant anti-CD33 immunotoxin HuM195/rGel.
Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis.
Min Chiu Li: a perspective in cancer therapy.
Myelodysplastic syndrome is not merely "preleukemia".
Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia.

Schools

Univ Of Il Coll Of Med
Cook Co Hospital
Presby Hospital
Mass Meml Hospital

Doctors Specialties

Internal Medicine
Oncology

Accepted Insurances

Awards

Fellow (FASCO)
Elected Member

Education

Boston University Medical Center
Rush University Medical Center
John H. Stroger Hospital of Cook County
University of Illinois College of Medicine

Hospital

University of Texas M.D. Anderson Cancer Center

Helpful Reviews

Give Anonymous Review

Similar Doctors

	Dr. Charles M. Nguyen, MD This Doctor is OpenDoctor Recommended.
	Dr. Alexander S. Kim, MD
	Dr. Fredrick B. Hagemeister, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Issa F. Khouri, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Jaffer A. Ajani, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Aaron J. Schueneman, MD This Doctor is OpenDoctor Recommended.
	Dr. Mark A. Farnie, MD This Doctor is OpenDoctor Recommended.
	Dr. Antoine G. Younis, MD This Doctor is OpenDoctor Recommended.
	Dr. Trang A. Bui, MD This Doctor is OpenDoctor Recommended.